CWF Editing - National Coverage Determination (NCD) 270.3
Blood-Derived Products for Chronic, Non-Healing Wounds

MLN Matters Number: MM12611 Revised
Related Change Request (CR) Number: 12611
Related CR Release Date: April 27, 2022
Effective Date: April 13, 2021
Related CR Transmittal Number: R11364OTN
Implementation Date: July 5, 2022, October 3, 2022, Requirement 5, CWF only

Note: We revised this Article due to a revised CR 12611. The CR revision didn’t affect the substance of the Article. We did revise the CR release date, transmittal number, and the web address of the CR. All other information is the same.

Provider Types Affected
This MLN Matters Article is for physicians, providers and suppliers billing Medicare Administrative Contractors (MACs) for services they provide to Medicare patients.

Provider Action Needed
In this Article, you’ll learn about:

- New edits for autologous Platelet-Rich Plasma (PRP) claims for diabetes and chronic ulcers

Make sure your billing staff knows about these changes.

Background
Effective for claims with dates of service (DOS) on and after April 13, 2021, CMS nationally covers autologous PRP for the treatment of chronic non-healing diabetic wounds under Section 1862(a)(1)(A) of the Social Security Act (the Act) for a duration of 20 weeks. This applies when using devices whose FDA-cleared indications include the management of exuding cutaneous wounds, such as diabetic ulcers.

We added or modified the following codes in the January 2022 update of the Medicare Physician Fee Schedule Database (MPFSDB) and HCPCS file – HCPCS G0460 and G0465. HCPCS G0460 descriptor was changed, and HCPCS G0465 is new. This was necessary to distinguish diabetic from non-diabetic wounds. The codes are effective retroactive back to the effective date of the policy, April 13, 2021:
• HCPCS G0460, Autologous platelet rich plasma for non-diabetic chronic wounds/ulcers, including phlebotomy, centrifugation, and all other preparatory procedures, administration and dressings, per treatment
• HCPCS G0465, PRP for diabetic chronic wounds or ulcers, using an FDA-cleared device for this indication, (Includes administration, dressings, phlebotomy, centrifugation, and all other preparatory procedures, per treatment).

**Key Points**

CR 12611 provides editing for autologous PRP claims for diabetes and chronic ulcers, HCPCS G0465, for claims which are performed more than 20 weeks after the DOS of the first HCPCS G0465. The edits will allow payment (at your MAC discretion) for such claims when the KX modifier is included on the claim.

You may refer to MLN Matters Article MM12403 for more information.

Your MAC decides coverage of autologous PRP for the treatment of:

• Chronic non-healing diabetic wounds beyond 20 weeks when you include the KX modifier on the claim (HCPCS G0465)
• All other chronic non-healing, non-diabetic wounds (HCPCS G0460)

Your MAC won't automatically adjust previously processed PRP claims for services performed on or after April 13, 2021. They may adjust such claims that you bring to their attention.

**More Information**

We issued CR 12611 to your MAC as the official instruction for this change.

For more information, find your MAC’s website.

**Document History**

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 28, 2022</td>
<td>We revised this Article due to a revised CR 12611. The CR revision didn't affect the substance of the Article. We did revise the CR release date, transmittal number, and the web address of the CR. All other information is the same.</td>
</tr>
<tr>
<td>February 16, 2022</td>
<td>Initial article released.</td>
</tr>
</tbody>
</table>

**Disclaimer:** Paid for by the Department of Health & Human Services. This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the
written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2020 American Medical Association. All rights reserved.

Copyright © 2013-2021, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@healthforum.com

The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliate